Kyowa Hakko Bio succeeded its bio-chemical business from Kyowa Hakko Kogyo and was established in 2008. Kyowa Hakko Kogyo can thus be regarded as the predecessor of Kyowa Hakko Bio.
Kyowa Hakko Kogyo
| 1949 | Establishment of Kyowa Hakko Kogyo. |
|---|---|
| 1951 | Introduced production technology of Streptomycin, an anti-tubercular drug from US pharmaceutical company Merck & Co. Inc., and succeeded in its mass production. |
| 1956 | Succeeded in the isolation and commercial mass-production of the anticancer drug MitomycinC. World's first invention of the process of L-Glutamic acid production by fermentation. Pioneered in the major business industry of amino-acid fermentation. |
| 1958 | Invention of the process of L-Lysine production by fermentation. Release of a plant growth regulator Gibberellin Kyowa (contributed to production of seedless grapes). |
| 1969 | Establishment of Kyowa Hakko USA. |
| 1973 | Establishment of Kyowa Hakko Europe. |
| 1981 | Establishment of the Bio Business Headquarters. |
| 2005 | Completion of the transition to an operating holding company (Pharmaceuticals and Bio-chemicals are its main pillars). |
| 2007 | Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group. |
Kyowa Hakko Bio
| 2008 | Establishment of Kyowa Hakko Bio (succeeded Bio-Chemical business from Kyowa Hakko Kogyo). Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group. |
|---|---|
| 2015 | Completion of Construction for Amino Acid Manufacturing Plant in Thailand |
| 2019 | Became a direct subsidiary of Kirin Holdings Company, Limited through transfer of shares |
| 2024 | Announced the transfer of the amino acid and human milk oligosaccharide businesses to a special purpose company that is a subsidiary of Meihua Holdings Group Co., Ltd. |
| 2025 | The amino acid and human milk oligosaccharide businesses were transferred to Plumino Precision Fermentation Japan Co., Ltd. |